Untangling the ethics of psychedelics for therapeutic care: how clinicians, researchers, and patients can handle key moral tradeoffs

Psychedelics for therapeutic care raise practical ethical dilemmas that do not fit neatly into existing medical frameworks. The discussion centers on what ethical responsibility should look like across the therapy model: informed consent and patient understanding, safe screening, appropriate clinical support during and after dosing, and the risks of coercion or misunderstanding when participants are vulnerable. It also considers how research and policy should address access and fairness, including who benefits, who bears the burdens, and how regulators and institutions can set standards for training, oversight, and accountability. The goal is to clarify ethical pathways so therapeutic use can be governed by patient-centered safety and transparency rather than hype.